Identifying the mediators of dapagliflozin-induced renal benefits in patients with CKD with or without T2DM: Post-hoc analysis of the DAPD-CKD trial

Contextualizing the advantages of early intervention in HR-SMM

Early reduction of albuminuria facilitated by finerenone contributes to optimal kidney and CV outcomes in patients with T2D: Mediation analysis of the FIDELIO-DKD and FIGARO-DKD trials

Predictive biomarkers for belimumab-induced renal response in patients with lupus nephritis: Post-hoc analyses of the BLISS-LN trial

Holistic care for enhancing cardiovascular-kidney-metabolic health: The AHA CKM health initiative

Novel assessment tool for predicting CKD progression and identifying high-risk individuals in early-stage CKD: The Klinrisk model